Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Walgreen

This article was originally published in The Rose Sheet

Executive Summary

Store openings contributed to a 14% rise in sales to $8.2 bil. for the fourth quarter (ended Aug. 31), while net earnings were up 11.9% to $277.1 mil., according to Walgreen. The firm opened 209 stores in the fourth quarter alone to total 4,227 locations. Store expansion in 2004 will be targeted to California, the Carolinas, Florida, Texas and Washington, and the retailer notes it is on track to reach 7,000 stores by 2010. Comparable store sales in Q4 were up 9.9%. Full year revenue was up 13.3% to $32.5 bil., with comparable store sales up 8.6%. Net earnings rose 15.4% to $1.18 bil. Walgreen notes it is budgeting more than $1 bil. in capital investments for the new fiscal year...

You may also be interested in...



Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

UsernamePublicRestriction

Register

RS011587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel